1,716 Shares in Masimo Co. (NASDAQ:MASI) Purchased by Stifel Financial Corp

Stifel Financial Corp purchased a new stake in Masimo Co. (NASDAQ:MASI) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,716 shares of the medical equipment provider’s stock, valued at approximately $229,000.

A number of other institutional investors and hedge funds also recently modified their holdings of MASI. NBC Securities Inc. grew its holdings in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the last quarter. HHM Wealth Advisors LLC grew its stake in shares of Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Masimo during the 2nd quarter worth $109,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Masimo in the 3rd quarter worth $118,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analyst Ratings Changes

MASI has been the subject of a number of research reports. Wells Fargo & Company boosted their price target on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Raymond James boosted their target price on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday. BTIG Research lifted their price target on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus restated a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $179.67.

Masimo Stock Down 0.0 %

Shares of NASDAQ:MASI opened at $170.97 on Monday. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of 117.91 and a beta of 1.01. The company has a 50 day moving average of $162.96 and a two-hundred day moving average of $136.32. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $180.97. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same period last year, the business earned $0.63 EPS. The business’s revenue was up 5.4% on a year-over-year basis. As a group, analysts forecast that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.